Patents Issued in March 15, 2016
  • Patent number: 9283178
    Abstract: Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: March 15, 2016
    Assignee: Allergan, Inc.
    Inventor: Vernon G. Wong
  • Patent number: 9283179
    Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: March 15, 2016
    Assignee: Rani Therapeutics, LLC
    Inventor: Mir Imran
  • Patent number: 9283180
    Abstract: A method and formulation for delivering an active compound in a vaporized state using low temperatures to vaporize the formulation. The formulation contains an inert non-reactive compound that lowers the heat of vaporization of the formulation, and the active compound. The formulation may optionally contain glycerin, alcohol, and/or water. Examples of inert non-reactive compounds that can sufficiently lower the heat of vaporization of the formulation include propylene glycol and polysorbate. The formulation can be vaporized using a hand-held low temperature vaporizer or atomizer.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: March 15, 2016
    Assignee: CHONG CORPORATION
    Inventors: Alexander ChinHak Chong, William P. Bartkowski, Marshall A. Thompson
  • Patent number: 9283181
    Abstract: The present invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the central nervous system (CNS). In some embodiments, the present invention provides methods including a step of administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of a lysosomal enzyme, a composition comprising a replacement enzyme for the lysosomal enzyme.
    Type: Grant
    Filed: June 25, 2011
    Date of Patent: March 15, 2016
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Pericles Calias, Jing Pan, Jan Powell, Lawrence Charnas, Thomas McCauley, Teresa Leah Wright, Richard Pfeifer, Zahra Shahrokh
  • Patent number: 9283182
    Abstract: The present invention relates to formulations of nucleotide reverse transcriptase inhibitors (NRTIs), preferably [2-(6-Amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid (tenofovir, PMPA), or a physiologically functional derivative thereof, suitable for topical application and their use in the prevention of HIV infections.
    Type: Grant
    Filed: September 24, 2010
    Date of Patent: March 15, 2016
    Assignees: The CONRAD Program of the Eastern Virginia Medical School (“CONRAD”), International Partnership for Microbicides, Inc.
    Inventor: Terrence C. Dahl
  • Patent number: 9283183
    Abstract: This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: March 15, 2016
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Mathai Mammen, YuHua Ji, YongQi Mu, Craig Husfeld, Li Li
  • Patent number: 9283184
    Abstract: The invention provides compositions and methods for delivering agents to localized regions, tissues, or organs in vivo by conjugating agent-loaded nanoparticles to cells having homing capability. The agents may be therapeutic or diagnostic agents such as cancer chemotherapeutic agents and imaging agents respectively.
    Type: Grant
    Filed: November 24, 2009
    Date of Patent: March 15, 2016
    Assignee: Massachusetts Institute of Technology
    Inventors: Darrell J. Irvine, Matthias Stephan, Jaehyun Moon, Anna Bershteyn
  • Patent number: 9283185
    Abstract: The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: May 27, 2011
    Date of Patent: March 15, 2016
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Bhushan Aggarwal
  • Patent number: 9283186
    Abstract: An amphoteric liposome composed of a mixture of lipids, said mixture comprising a cationic amphiphile, an anionic amphiphile and optionally one or more neutral amphiphiles, at least one of said cationic and anionic amphiphiles being chargeable and the respective amounts of said cationic and anionic amphiphiles being selected such there is a stoichiometric excess of positively charged cationic amphiphile at a first lower pH, a stoichiometric excess of negatively charged anionic amphiphile at a second higher pH and said mixture has an isoelectric point intermediate said first and second pHs; characterised in that said positively charged cationic and negatively charged anionic amphiphiles are adapted to form a lipid salt with one another at said isoelectric point. Also disclosed are methods of predicting the fusogenicity of an amphoteric liposome at a given pH, formulating an amphoteric liposome and loading an amphoteric liposome with a cargo moiety.
    Type: Grant
    Filed: January 13, 2012
    Date of Patent: March 15, 2016
    Assignee: Marina Biotech, Inc.
    Inventors: Steffen Panzner, Silke Lutz, Evgenios Siepi, Claudia Müller
  • Patent number: 9283187
    Abstract: The invention relates to a hemostatic composition in powder form comprising collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen, and at least one monosaccharide, and optionally, at least one compound selected from coagulation factors and glycosaminoglycans. The invention further relates to a method for preparing such composition, and to a unit comprising such composition and a spraying device.
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: March 15, 2016
    Assignee: BIOM'UP
    Inventors: Christian Gagnieu, Patricia Forest, Sylvain Picot
  • Patent number: 9283188
    Abstract: Delivery systems for incorporating functional compounds into substrates for use in various consumer products are disclosed. Specifically, the delivery system includes a carrier component comprising an ultrasonically energized adsorbent and one or more functional compounds. The ultrasonically energized adsorbent can adsorb the desired functional compounds and bind the functional compounds to the surface of the substrate.
    Type: Grant
    Filed: September 8, 2006
    Date of Patent: March 15, 2016
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventors: Robert Allen Janssen, Earl C. McCraw, Jr., Kimberlee Fay Thompson, John Gavin MacDonald, Thomas David Ehlert, Patrick Sean McNichols
  • Patent number: 9283189
    Abstract: Disclosed is a sustained-release preparation of ivabradine or pharmaceutically acceptable salts thereof. The preparation contains ivabradine or pharmaceutically acceptable salts thereof and a sustained-release framework material, wherein the sustained-release framework material is selected from polyoxyethylene, or a mixture of polyoxyethylene and polyvinyl acetate or polyvinyl pyrrolidone.
    Type: Grant
    Filed: June 18, 2012
    Date of Patent: March 15, 2016
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Kai Liu, Yuxia Wu
  • Patent number: 9283190
    Abstract: A high-efficacy, long-acting, slow-release formulation of the poorly soluble drug, comprising solid dispersion of the poorly soluble drug, silica nanoparticles loaded with the poorly soluble drug, matrix material, and release enhancer, wherein the mass ratio of these components is solid dispersion of the poorly soluble drug: silica nanoparticles loaded with the poorly soluble drug: matrix material: release enhancer=1: 0.5˜1.25: 0.1˜0.3: 0.1˜0.3; the said solid dispersion of the poorly soluble drug contains povidone K30, soybean lecithin, and acrylic resin IV, wherein the mass ratio of the drug and the accessory materials is poorly soluble drug: povidone K30: soybean lecithin: acrylic resin IV=1: 1˜3: 0.3˜0.8: 0.2˜0.5. Compared with the existing formulations, the in vivo half life of the high-efficacy, long-acting formulation of the poorly soluble drug disclosed in this invention is 2.3˜14.8 times longer while the mean residence time (MRT) of which is 7.94˜4.
    Type: Grant
    Filed: November 23, 2009
    Date of Patent: March 15, 2016
    Assignee: JIANGSU UNIVERSITY
    Inventors: Ximing Xu, Jiangnan Yu, Yuan Zhu, Xia Cao
  • Patent number: 9283191
    Abstract: A compressed chewing gum tablet includes at least a first and a second chewing gum module, the first chewing gum module including a first chewing gum composition including at least a first active ingredient and chewing gum granules containing gum base, the second chewing gum module including a second chewing gum composition including at least a second active ingredient and chewing gum granules containing gum base, wherein the first active ingredient is a pharmaceutically active ingredient, and the second active ingredient is selected from the group consisting of pharmaceutically active ingredients and enhancers, wherein the gum base content of the first and second chewing gum modules is different.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: March 15, 2016
    Assignee: FERTIN PHARMA A/S
    Inventors: Carsten Andersen, Gitte Lorenzen, Nicolai Arent, Bitten Thorengaard, Helle Wittorff
  • Patent number: 9283192
    Abstract: In one aspect, the present invention is concerned with a treatment where it is desired that an active agent is designed to be released in a prolonged manner at a time point some time after administration of the active agent. The present invention is particularly suited to administering an agent which may be released whilst a subject is sleeping, shortly before waking and continues to administer the drug during the early waking hours. As well as treating certain conditions by a particular regime, the invention also provides novel formulations for a delayed, followed by a prolonged release of drug.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: March 15, 2016
    Assignee: UNIVERSITY OF STRATHCLYDE
    Inventors: Alexander Mullen, Howard Stevens, Sarah Eccleston
  • Patent number: 9283193
    Abstract: Methods are provided for coating crystalline microparticles with an active agent by altering the surface properties of the microparticles in order to facilitate favorable association on the microparticle by the active agent. Type of surface properties that are altered by the disclosed methods include by electrostatic properties, hydrophobic properties and hydrogen bonding properties.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: March 15, 2016
    Assignee: MannKind Corporation
    Inventors: Keith A. Oberg, Joseph Sulner, Marshall L. Grant
  • Patent number: 9283194
    Abstract: A method for intracellular delivery of single proteins or other cargo molecules by encapsulation within nanocapsules formed by interfacial polymerization of one or more types of monomers and selected protease cleavable cross-linkers is provided. The thin positively charged capsules are readily brought into the cytosol of target cells by endocytosis. The capsules are degraded by the action of endogenous proteases or co-delivered proteases on the cross-linkers releasing the functional cargo unaltered. The cross-linkers can be adapted to be cleavable by specific enzymes selected from available intracellular enzymes within the target cell or co-delivered or self-cleaving when the cargo itself is a protease. The nanocapsules produced by the methods have been shown to have long-term stability, high cell penetration capability, low toxicity and efficient protease-modulated specific degradability without affecting cargo protein function.
    Type: Grant
    Filed: April 18, 2011
    Date of Patent: March 15, 2016
    Assignee: The Regents of the University of California
    Inventors: Yi Tang, Zhen Gu, Yunfeng Lu, Ming Yan, Anuradha Biswas, Guoping Fan
  • Patent number: 9283195
    Abstract: The invention encompasses methods and kits used in the identification of invasive glioblastoma based upon the expression of TROY. The methods and kits also allow prediction of disease outcome as well as therapeutic outcome.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: March 15, 2016
    Assignee: The Translational Genomics Research Institute
    Inventor: Nhan Tran
  • Patent number: 9283196
    Abstract: The invention is directed to the use of a compound of formula I as defined herein, a pharmaceutically acceptable salt thereof; or a pharmaceutical composition containing a compound of formula I, in treating a mammal, including a human, for a psychiatric disorder or condition selected from the group consisting of depression, mood disorders, anxiety, schizophrenia, bipolar disorder (also referred to as manic-depressive disorder), addiction, cognitive impairment, Parkinson's and Alzheimer's diseases.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: March 15, 2016
    Assignee: MediSynergics, LLC
    Inventors: Dennis Michael Godek, Harry Ralph Howard
  • Patent number: 9283197
    Abstract: The present invention provides pharmaceutical formulations of levorotatory-epinephrine, l-epinephrine, more potent and less toxic than existing pharmaceutical formulations of epinephrine, along with methods of producing and using these pharmaceutical formulations of l-epinephrine.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: March 15, 2016
    Inventor: Jugal K. Taneja
  • Patent number: 9283198
    Abstract: The subject invention provides materials and methods for treating various health conditions, including the prevention and/or treatment of a viral infection. In a preferred embodiment, a cysteamine compound is administered to a subject to treat an influenza virus infection. More preferably, a cysteamine compound is administered to a subject to treat influenza A, influenza B, influenza C virus infections, including avian influenza virus subtypes (such as H5N1 avian influenza virus).
    Type: Grant
    Filed: April 4, 2013
    Date of Patent: March 15, 2016
    Assignee: OBIO PHARMACEUTICAL (H.K.) LIMITED
    Inventors: Hao Yi Liang, Francis Chi, Qingfu Xu, Bill Piu Chan
  • Patent number: 9283199
    Abstract: Halogenated aliphatic carboxylic acids, salts and/or oligomers or polymers thereof, which exhibit a devitalizing effect of neoplastic tissues, are disclosed. Methods and uses that utilize these compounds for the treatment of medical conditions associated with a neoplastic tissue are also disclosed. Further disclosed are methods and uses that utilize these compounds for reducing or abolishing blood and lymph as well local dissemination of malignant neoplastic cells during a surgical removal thereof, thereby preventing recurrences and distance metastases, and/or inducing immune response to potentially malignant, pre-malignant and/or malignant cells. Further disclosed are novel oligomeric forms of halogenated aliphatic carboxylic acids, pharmaceutical compositions containing same and uses thereof.
    Type: Grant
    Filed: June 9, 2010
    Date of Patent: March 15, 2016
    Assignee: Cimas Limited
    Inventors: Shalva Mardi, Rosa Mardi, Gymsher Mardi, Laura Mardi, Shimon Slavin
  • Patent number: 9283200
    Abstract: The present invention provides for methods and compositions for treating medium chain acyl-CoA dehydrogenase deficiency. It is based, at least in part, on the discovery that phenylbutyrate can serve as a substrate for medium chain acyl-CoA dehydrogenase. In non-limiting embodiments, phenylbutyrate and/or another source of phenylacetate is administered as a chaperone treatment to patients suffering from medium chain acyl-CoA dehydrogenase deficiency.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: March 15, 2016
    Inventors: Al-Walid Mohsen Mohamed, Gerard Vockley
  • Patent number: 9283201
    Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent obesity.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 15, 2016
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventor: Joseph S. Zakrzewski
  • Patent number: 9283202
    Abstract: Methods have been developed for incorporation of peracid compounds and related compositions into a non-aqueous medium. The peracid incorporated into the non-aqueous medium is stable and keeps its chemical and antimicrobial activity for extended durations. The non-aqueous medium may be removed just prior to or during application of the peracid.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: March 15, 2016
    Assignee: CHD Bioscience, Inc.
    Inventors: Edwin D. Neas, Michael K. Handley, Kevin S. Marchitto, Stephen T. Flock, Charles Henry
  • Patent number: 9283203
    Abstract: This invention relates to compositions, and methods of use thereof, for (i) enhancing executive cognitive function(s) (for example, decision making, planning, working memory, multitasking, judgment, numerical problem-solving, reading comprehension), and/or (ii) increasing blood flow in brain vasculature, comprising administering to a subject in need thereof, certain polyphenols such as flavanols, procyanidins, or pharmaceutically acceptable salts or derivatives thereof.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: March 15, 2016
    Assignee: MARS, INCORPORATED
    Inventors: Stephen French, Amar P. Inamdar, Ian Andrew Macdonald, Susan T. Francis
  • Patent number: 9283204
    Abstract: This invention relates to extracts and refined fractions of a traditional Chinese medicinal herb, Alpinia officinarum (AO), components thereof, and the use of such compounds and compositions to treat neurodegenerative or neuropathological conditions or to inhibit aggregation of a-synuclein.
    Type: Grant
    Filed: August 10, 2011
    Date of Patent: March 15, 2016
    Assignee: The Hong Kong University of Science and Technology
    Inventors: Nancy Yuk Yu Ip, Kenny Ka Kin Chung, Fanny Chui Fun Ip, Guangmiao Fu
  • Patent number: 9283205
    Abstract: The present invention relates to a method for extracting treatment ingredients for gastrointestinal diseases from the bark of Liriodendron tulipifera, the treatment ingredients containing epitulipinolide and costunolide as active ingredients, and to a therapeutic agent for gastrointestinal diseases, containing epitulipinolide and costunolide extracted using said method.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: March 15, 2016
    Assignee: Cho Dang Pharm. Co., Ltd.
    Inventor: Nak Doo Kim
  • Patent number: 9283206
    Abstract: The invention relates to the use of 4,6,4?-trimethylangelicin (TMA) and structural analogs thereof to prepare a medicament for the treatment of cystic fibrosis with the primary objective of correcting the defective CFTR in a sub-group of cystic fibrosis patients consisting of patients carrying the F508del-CFTR mutation.
    Type: Grant
    Filed: June 13, 2012
    Date of Patent: March 15, 2016
    Assignees: Azienda Ospedaliera Universitaria Integrata di Verona, Universita' degli Studi di Ferrara, Universita' degli Studi di Bari, Rare Partners S.r.l.
    Inventors: Giulio Cabrini, Valeria Casavola, Roberto Gambari
  • Patent number: 9283207
    Abstract: Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (?) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-? or the inhibition of PDE4.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: March 15, 2016
    Assignee: Celgene Corporation
    Inventors: George W. Muller, Peter H. Schafer, Hon-Wah Man, Chuansheng Ge
  • Patent number: 9283208
    Abstract: Medicaments and methods for treating cancer are disclosed.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: March 15, 2016
    Assignee: NIIKI PHARMA INC.
    Inventor: Hooshmand Sheshbaradaran
  • Patent number: 9283209
    Abstract: Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: March 15, 2016
    Assignee: NOVARTIS AG
    Inventors: Indrajit Ghosh, Jia-Ai Zhang
  • Patent number: 9283210
    Abstract: Aspects of the present invention relate to amorphous form of mirabegron, amorphous solid dispersion of mirabegron, process for its preparation, processes for preparation of a form crystal and ? form crystal of mirabegron and pharmaceutical composition thereof.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: March 15, 2016
    Assignee: DR. REDDY'S LABORATORIES LTD.
    Inventors: Vishweshwar Peddy, Rajesham Boge
  • Patent number: 9283211
    Abstract: The disclosure teaches counter-intuitive methods for treating stomatitis using oral mTOR inhibiting preparations such as preparations of microcapsules and nanoparticles including an inhibitor of the mammalian target of rapamycin. The methods, preparations and other teachings are useful in various respects, especially for assisting in the treatment, prevention and management of stomatitis in feline subjects and, most especially, the treatment and management of Feline Chronic Gingivo-Stomatitis (FCGS), with secondary applications also related to management of gingivitis and autoimmune mucosal disorders. Disclosed embodiments illustrate multi-week dosing regimens and also address needs for alternative preparations or manufacturing processes that ensure efficacy while improving other performance characteristics such as storage stability, biodistribution, dosage cost, etc.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: March 15, 2016
    Assignee: Rapamycin Holdings, LLC
    Inventor: Dana M Vaughn
  • Patent number: 9283212
    Abstract: The present invention relates to unique delivery systems and the use of an imidazobenzodiazepine derivative, such as flumazenil either alone or in combination with other receptor antagonists in the treatment of disease or medical disorders.
    Type: Grant
    Filed: February 19, 2010
    Date of Patent: March 15, 2016
    Assignee: PALMAYA PTY LTD
    Inventor: Alexander George Brian O'Neil
  • Patent number: 9283213
    Abstract: The present invention is directed to novel dihydropyridin-2(1H)-one compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors and/or Neurokinin-3 (NK3) receptor antagonists, pharmaceutical compositions comprising such compounds, and methods of making and using the same.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: March 15, 2016
    Assignee: Nivalis Therapeutics, Inc.
    Inventors: Xicheng Sun, Jian Qiu
  • Patent number: 9283214
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: March 15, 2016
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Patent number: 9283215
    Abstract: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: March 15, 2016
    Assignee: Celgene Corporation
    Inventor: Jerome B. Zeldis
  • Patent number: 9283216
    Abstract: Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as a immediate release product as a single dose. The controlled release nature of the table prevents the accumulation of orally effective amounts of opioid antagonist when taken normally. The opioid antagonist is contained in a controlled-release matrix and released, over time, with the opioid.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: March 15, 2016
    Assignee: Purdue Pharma L.P.
    Inventors: Frank S. Caruso, Huai-Hung Kao
  • Patent number: 9283217
    Abstract: The present invention relates to a method for treating skin diseases and skin conditions in a patient in need thereof which comprises of administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of 7-(1H-Imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline, or its individual enantiomers or the tautomers thereof, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: March 15, 2016
    Assignee: Allergan, Inc.
    Inventors: Mohammed I. Dibas, Edward C. Hsia, John E. Donello, Daniel W. Gil
  • Patent number: 9283218
    Abstract: The present invention relates to an amorphous solid dispersion comprising a tetrazole derivative of the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. The solid dispersion of the present invention comprises a water-soluble polymer or an acid so as to improve the solubility of its active ingredient, i.e., the tetrazole derivative of the formula (I), thereby improving its absorption rate, and thus can be effectively used to reduce multi-drug resistance (MDR) in cancer cells.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: March 15, 2016
    Assignee: HANMI PHARM. CO., LTD
    Inventors: Yong Il Kim, Jun Young Choi, Young Keun Choi, Jae Hyun Park, Jong Soo Woo
  • Patent number: 9283219
    Abstract: The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: March 15, 2016
    Assignee: Cynapsus Therapeutics, Inc.
    Inventors: Nathan John Bryson, Anthony John Giovinazzo, Scott David Barnhart, Michael Clinton Koons
  • Patent number: 9283220
    Abstract: Provided are compositions comprising opioid antagonists, such as naltrexone naloxone, or nalmefene, or their pharmaceutically acceptable salts, and methods for treating conditions caused by the varicella-zoster virus therewith.
    Type: Grant
    Filed: March 31, 2011
    Date of Patent: March 15, 2016
    Assignee: IMUNEKS FARMA ILAC SANAYI VE TICARET ANONIM SIRKETI PAK IS MERKEZI
    Inventors: Ibrahim Mustafa Iskender Pisak, Semra Bingol, Mehmet Levent Selamoglu, Mehmet Pisak
  • Patent number: 9283221
    Abstract: Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as a immediate release product as a single dose. The controlled release nature of the table prevents the accumulation of orally effective amounts of opioid antagonist when taken normally. The opioid antagonist is contained in a controlled-release matrix and released, over time, with the opioid.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: March 15, 2016
    Assignee: Purdue Pharma L.P.
    Inventors: Frank S. Caruso, Huai-Hung Kao
  • Patent number: 9283222
    Abstract: Inhibitors of poly(ADP-ribose)polymerase, ways to make them and methods of treating patients using them are disclosed.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: March 15, 2016
    Assignee: AbbVie Inc.
    Inventors: Virajkumar B. Gandhi, Vincent L. Giranda, Jianchun Gong, Thomas D. Penning, Gui-Dong Zhu
  • Patent number: 9283223
    Abstract: A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years.
    Type: Grant
    Filed: February 17, 2014
    Date of Patent: March 15, 2016
    Assignee: Gilead Sciences, Inc.
    Inventors: Michael J. Gerber, Christopher Dufton
  • Patent number: 9283224
    Abstract: The present invention relates to substituted pyrimidinyl-pyrrole compounds of formula (I) which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular Janus kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such compounds or the pharmaceutical compositions containing them.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: March 15, 2016
    Assignee: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Maria Gabriella Brasca, Tiziano Bandiera, Jay Aaron Bertrand, Paola Gnocchi, Danilo Mirizzi, Marcella Nesi, Achille Panzeri
  • Patent number: 9283225
    Abstract: Compounds of the formula I in which Het, R3 and R4 have the meanings indicated in Claim 1, are inhibitors of RON and can be employed, for the treatment of cancer.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: March 15, 2016
    Assignee: Merck Patent GmbH
    Inventors: Wolfgang Staehle, Oliver Schadt, Christine Knuehl, Manja Friese-Hamim, Bayard R. Huck, Andreas Goutopoulos, Nadia Brugger
  • Patent number: 9283226
    Abstract: The invention provides compounds of the formula (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R1 and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom ? with respect to the NR2R3 group and provided that the oxo group when present is located at a carbon atom ? with respect to the NR2R3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; R1 is an aryl or heteroaryl group; and R2, R3, R4 and R5 are as defined in the claims.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: March 15, 2016
    Assignees: ASTEX THERAPEUTICS LIMITED, THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Valerio Berdini, Gordon Saxty, Marinus Leendert Verdonk, Steven John Woodhead, Paul Graham Wyatt, Robert George Boyle, Hannah Fiona Sore, David Winter Walker, Ian Collins, Robert Downham, Robin Arthur Ellis Carr
  • Patent number: 9283227
    Abstract: A process for the preparation of a solid, orally administrable pharmaceutical composition, comprising 5-chloro-N-({(5)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide comprising preparing granules in hydrophilized form using fluidized bed granulation for moist granulation, adding additives, compressing to form a tablet, and coating the tablet.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: March 15, 2016
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventor: Klaus Benke